The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function
Status:
Completed
Trial end date:
2000-09-01
Target enrollment:
Participant gender:
Summary
The renin angiotensin system (RAS) plays an important physiological and pathophysiological
role in the control of blood pressure and plasma volume. Inhibition of the RAS is useful in
the treatment of hypertension, cardiac failure and in some patients with myocardial
infarction. Several recent clinical trials with angiotensin converting enzyme inhibitors
(ACEI) have shown that they also reduce the incidence of myocardial infarction, but the
mechanisms underlying this anti-ischemic effect are poorly understood. ACEI reduce
angiotensin II synthesis and prevent bradykinin degradation. Results from ongoing studies in
the Cardiology Branch (Protocol 95-H-0099) designed to investigate the link between ACEI and
the vascular endothelium indicate that ACEI improve peripheral endothelial function, an
effect that is partially mediated by bradykinin. The current protocol is designed to
investigate whether the beneficial effects of ACEI on peripheral endothelial function are
also due to inhibition of angiotensin II. The recent development of selective angiotensin II
type 1 (AT1) receptor antagonists allows us to specifically examine the effects of
angiotensin II on vasomotor activity.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Angiotensin II Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Angiotensinogen Giapreza